Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Varga

Showing results (101-110 of 110) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 110 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2024
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast CancerKomal L Jhaveri, Melissa K Accordino, Philippe L Bedard, et al.
Oncotarget|March 9, 2018
Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancersLuc Cabel, Alina Fuerea, Ludovic Lacroix, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2018
Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back doorLoic Verlingue, Antoine Hollebecque, Ludovic Lacroix, et al.
American Journal of Hematology|June 24, 2021
Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B-cell lymphoma: Results of LNH-EP1 studyClémentine Sarkozy, Jean-Marie Michot, Cyril Quivoron, et al.
European Journal of Cancer (Oxford, England : 1990)|April 9, 2025
Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b studyPhilippe L Bedard, Komal L Jhaveri, Melissa K Accordino, et al.
NPJ Breast Cancer|April 17, 2021
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancerLillian M Smyth, Gerald Batist, Funda Meric-Bernstam, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2020
The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical studyJean-Marie Michot, Ariane Lappara, Jérôme Le Pavec, et al.
Cancer Discovery|April 3, 2017
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 TrialChristophe Massard, Stefan Michiels, Charles Ferté, et al.
The New England Journal of Medicine|April 30, 2015
Rociletinib in EGFR-mutated non-small-cell lung cancerLecia V Sequist, Jean-Charles Soria, Jonathan W Goldman, et al.
Cancer Discovery|January 20, 2023
Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural MesotheliomaFrançois-Xavier Danlos, Matthieu Texier, Bastien Job, et al.
Pageof 11

Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2024
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast CancerKomal L Jhaveri, Melissa K Accordino, Philippe L Bedard, et al.
Oncotarget|March 9, 2018
Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancersLuc Cabel, Alina Fuerea, Ludovic Lacroix, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2018
Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back doorLoic Verlingue, Antoine Hollebecque, Ludovic Lacroix, et al.
American Journal of Hematology|June 24, 2021
Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B-cell lymphoma: Results of LNH-EP1 studyClémentine Sarkozy, Jean-Marie Michot, Cyril Quivoron, et al.
European Journal of Cancer (Oxford, England : 1990)|April 9, 2025
Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b studyPhilippe L Bedard, Komal L Jhaveri, Melissa K Accordino, et al.
NPJ Breast Cancer|April 17, 2021
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancerLillian M Smyth, Gerald Batist, Funda Meric-Bernstam, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2020
The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical studyJean-Marie Michot, Ariane Lappara, Jérôme Le Pavec, et al.
Cancer Discovery|April 3, 2017
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 TrialChristophe Massard, Stefan Michiels, Charles Ferté, et al.
The New England Journal of Medicine|April 30, 2015
Rociletinib in EGFR-mutated non-small-cell lung cancerLecia V Sequist, Jean-Charles Soria, Jonathan W Goldman, et al.
Cancer Discovery|January 20, 2023
Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural MesotheliomaFrançois-Xavier Danlos, Matthieu Texier, Bastien Job, et al.
Pageof 11